Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

302.70DKK
10:59am EST
Change (% chg)

kr.-1.20 (-0.39%)
Prev Close
kr.303.90
Open
kr.305.00
Day's High
kr.306.00
Day's Low
kr.300.70
Volume
303,338
Avg. Vol
417,969
52-wk High
kr.413.20
52-wk Low
kr.266.40

Summary

Name Age Since Current Position

Lars Rasmussen

58 2016 Independent Chairman of the Board

Anders Goetzsche

49 2017 Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President

Lene Skole

57 2015 Deputy Chairman of the Board

Peter Anastasiou

2017 Executive Vice President, North America

Lars Bang

54 Executive Vice President, Supply Operations & Engineering

Anders Gersel Pedersen

65 2011 Executive Vice President, Research and Development

Jacob Tolstrup

45 2017 Executive Vice President, Commercial Operations

Mona Elisabeth Elster

54 2010 Director, Employee Representative

Lars Holmqvist

57 2015 Director

Jeremy Levin

63 2017 Director

Joern Mayntzhusen

50 2008 Directors, Employee Representative

Henrik Sindal Jensen

48 2014 Director, Employee Representative

Jesper Ovesen

60 2015 Independent Director

Palle Holm Olesen

Vice President Investor Relations

Biographies

Name Description

Lars Rasmussen

Mr. Lars Rasmussen has served as Independent Chairman of the Board of Directors at H. Lundbeck A/S since March 31, 2016. Before that, he has been Independent Director of the Company since March 21, 2013. He is Member of the Company’s Audit Committee and Chairman of Remuneration and Scientific Committees. He has been Chief Executive Officer of Coloplast A/S since 2008 and Member of the company's Executive Management since 2001. He has management experience in global med-tech. He was responsible for various functions in the group, including global sales, innovation and production, both in Denmark and the United States. He is Member of the Board of William Demant Holding A/S.

Anders Goetzsche

Mr. Anders Goetzsche is Executive Vice President and Chief Financial Officer of H. Lundbeck A/S and he has been appointed Interim Chief Executive Officer of the Company effective as of November 1, 2017. He joined the Company in 2007. Prior to that, he was Chief Financial Officer for the Berlingske Officin, Director of Group Accounting and Reporting at Group 4 Falck and Sales Manager with the SAS Institute. He started his career in 1991 at PriceWaterhouseCoopers. Mr. Goetzsche is Member of the Board of Veloxis Pharmaceuticals A/S and Chairman of the Board of Rosborg Moebler A/S. He received a Master of Science degree in Accounting from Syddansk Universitet (University of Southern Denmark) in 1991, and became State Authorized Public Accountant in 1997.

Lene Skole

Ms. Lene Skole has been Deputy Chairman of the Board at H. Lundbeck A/S since March 25, 2015. She is CEO of Lundbeck Foundation and holds directorships in two subsidiaries. She is Member of the Remuneration and Scientific Committees of the Company. She also serves as Deputy Chairman of the Boards of DONG Energy A/S, Falck A/S and ALK-Abello A/S and is Board Member of Tryg A/S and Tryg Forsikring A/S.

Peter Anastasiou

Mr. Peter E. Anastasiou has been appointed Executive Vice President, North America at H. LUNDBECK A/S effective as of November 1, 2017. Peter Anastasiou serves as President of Lundbeck North America, overseeing the operations of both the U.S. and Canadian businesses. Peter Anastasiou has been with Lundbeck since 2009 and has since early 2016 served as President of Lundbeck U.S. where he oversees all aspects of the U.S. value chain, directing all Commercial, Drug Development and Corporate activities. Prior to that he served as U.S. Chief Commercial Officer, during which time he directed the Commercial operations of the company’s Psychiatry and Neurology franchises. Since mid-2016, Peter Anastasiou has had the responsibility for North America including Canada. Before joining Lundbeck, Peter Anastasiou held a series of leadership roles within neuroscience-focused pharmaceutical organizations. He served as Vice President of Marketing and Reimbursement at Neuronetics, Inc., and as Director of Abilify U.S. Marketing at Bristol-Meyers Squibb Company. He began his career at Eli Lilly and Company, where he held a variety of Marketing and Sales positions over the course of 11 years, including participation in the global launch of Cymbalta.

Lars Bang

Mr. Lars Bang serves as Executive Vice President, Supply Operations & Engineering at H. Lundbeck A/S. He began his career at the Company in 1988 as Trainee in Research & Development (R&D). Over the years, he held such positions as Lunbeck's Divisional Director for Corporate Planning and Strategy; Group Senior Vice President Supply Operations and Engineering since 2003, and Senior Vice President, Sales & Marketing, among others. Mr. Bang is Member of the Board of Directors of Fertin Pharma A/S and OB Holding. He obtained a Master of Science degree in Engineering from Danmarks Tekniske Universitet in 1987 and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School in 1989.

Anders Gersel Pedersen

Dr. Anders Gersel Pedersen M.D., Ph.D. has served as Executive Vice President, Research and Development at H. Lundbeck A/S since September 7, 2011. He joined the Company in 2000 as Vice President of International Clinical Research and was later appointed Executive Vice President of Drug Development. Prior to Lundbeck, he worked for Eli Lilly for 11 years, including ten years as a director overseeing worldwide clinical research in oncology. He started his carrier as researcher at Copenhagen hospitals. Dr. Gersel Pedersen has experience as Member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. He serves as Member of the Board of Directors of ALK-Abello A/S and Deputy Chairman of the Boards of Bavarian Nordic A/S and Genmab A/S. He holds a degree in Medicine.

Jacob Tolstrup

Mr. Jacob Tolstrup has been appointed Executive Vice President, Commercial Operations at H. Lundbeck A/S effective as of November 1, 2017. He has previously been Executive Vice President, Corporate Functions at the Company. Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in a number of positions including Finance, Investor Relations and Communication and has worked in Lundbeck affiliates in the US for approximately four years. He is head of Corporate Functions which comprises Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs. Jacob Tolstrup holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.

Mona Elisabeth Elster

Ms. Mona Elisabeth Elster has served as Employee Representative on the Board of Directors of H. Lundbeck A/S since 2010. She joined the Company in 2004. In 2009, she was appointed Senior Laboratory Technician. Previously, she worked at the Carlsberg Research Center; the Royal Veterinary and Agricultural University in Denmark, the Faculty of Pharmaceutical Sciences under the University of Copenhagen, and Danisco. Ms. Elster finished her Lab Technician course in 1984 and received a Marketing Diploma in 1989.

Lars Holmqvist

Mr. Lars Holmqvist has been Director of H. Lundbeck A/S since March 25, 2015. He is Member of the Audit Committee. He holds Master of Science in business administration. Lars Holmqvist is Senior Advisor within healthcare at Bain Capital. He previously served as Vice President responsible for sales and marketing at Pharmacia. In addition, he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO and Agilent Technologies. Lars Holmqvist’s special qualifications for serving on Lundbeck’s Board of Directors include his international management experience, his expertise in finance and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry. Lars Holmqvist is Board Member at Lundbeckfonden, ALK Abello A/S, Tecan AG and BPL Ltd.

Jeremy Levin

Dr. Jeremy M. Levin has served as Member of the Board of H. Lundbeck A/S since March 30, 2017. He is Member of the Company’s Scientific Committee.

Joern Mayntzhusen

Mr. Joern Mayntzhusen has been Employee Representative on the Board of Directors of H. Lundbeck A/S since 2008. He is Project Director at the Company. He joined Lundbeck in 2002 and has since been responsible for Production Planning and Costing and served as Head of Customer Supply. Mr. Mayntzhusen started his carrier at Handelsbanken (1986-1990). Later on, he spent two years at Thule Air Base with Greenland Contractors (1990-1992). In 1992 he started studying for his Bachelor of Science degree and was employed as Logistic Assistant with Braun Nordic (1993-1997). For the next two years Mr. Mayntzhusen worked as Business Management Advisor with Mellemfolkeligt Samvirke in Zimbabwe. Prior to joining Lundbeck, he was Nordic Logistic Manager with Moulinex Krups (1999-2002). Mr. Mayntzhusen obtained a Bachelor of Science degree in Logistics (HD(L)) from Copenhagen Business School in 1995, and a Master of Business Administration degree from Edinburgh Business School in 2002.

Henrik Sindal Jensen

Mr. Henrik Sindal Jensen has been Director, Employee Representative at H. Lundbeck A/S since March 26, 2014. He is Principal Scientist.

Jesper Ovesen

Mr. Jesper Ovesen has been Independent Director of H. Lundbeck A/S since March 25, 2015. He is also Member of the Audit Committee. He holds Master of Science in finance and is state authorized public accountant. Jesper Ovesen most recently held the position of Executive Chairman of Nokia Siemens Networks BV. Prior to this, he served as CFO in TDC A/S, Lego A/S and Danske Bank A/S and as Finance Director at Novo Nordisk A/S. Jesper Ovesen’s special qualifications for serving on Lundbeck’s Board of Directors include his international management experience and his expertise in finance, accounting and international capital markets. Jesper Ovesen is Deputy Chairman of the Board of Directors of Scandinaviska Enskilda Banken AB and member of the Board of Directors of ConvaTec Group PLC and Sunrise Communications Group AG.

Palle Holm Olesen